Xenon Pharmaceuticals reported the expansion of its ion channel product pipeline with XEN496, active ingredient ezogabine, a Kv7 potassium channel modulator for the potential treatment of epilepsy. Based on feedback from the FDA, Xenon anticipates initiating a single, pivotal Phase 3 clinical trial in approximately mid-2019 examining XEN496’s efficacy as a precision medicine treatment of KCNQ2 epileptic encephalopathy or EIEE7, a rare, severe, pediatric epilepsy. Ezogabine was originally approved by the FDA in June 2011 as an adjunctive treatment for adults with focal seizures with or without secondary generalization.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.